Acrivon Therapeutics, Inc. (ACRV) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-22

Acrivon Therapeutics, Inc. (ACRV) has filed 29 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-22. 2 Form 8-K material event filings were reported by ACRV in the last 90 days. InsiderAlpha tracks every ACRV SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Acrivon Therapeutics, Inc. (ACRV)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001781174

90-Day SEC Filing Activity

Form 4 filings (90d)	29
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-06-22

Recent ACRV Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-21	Blume-Jensen Peter	President and CEO	F — Tax withholding / forfeiture	13.7K	$1.79	$25K	SEC
2026-05-18	Magovcevic-Liebisch Ivana	Insider	A — Grant or award	9.4K	$0.00	—	SEC
2026-05-18	Peterson Katharine	Chief Accounting Officer	A — Grant or award	14.2K	$0.00	—	SEC
2026-05-18	Blume-Jensen Peter	President and CEO	A — Grant or award	72.7K	$0.00	—	SEC
2026-05-18	Shacham Sharon	Insider	A — Grant or award	9.4K	$0.00	—	SEC
2026-05-18	Palani Santhosh	Insider	A — Grant or award	9.4K	$0.00	—	SEC
2026-05-18	Blume-Jensen Peter	President and CEO	A — Grant or award	180.1K	$0.00	—	SEC
2026-05-18	Devroe Eric	Chief Operating Officer	A — Grant or award	73.0K	$0.00	—	SEC
2026-05-18	BAUM CHARLES M	Insider	A — Grant or award	9.4K	$0.00	—	SEC
2026-05-18	DiRocco Derek	Insider	A — Grant or award	9.4K	$0.00	—	SEC
2026-05-18	Miller Mary	Chief Legal Officer	A — Grant or award	49.8K	$0.00	—	SEC
2026-05-18	Gamelin Erick	Chief Development Officer	A — Grant or award	38.6K	$0.00	—	SEC
2026-05-18	Mirza Mansoor Raza	Chief Medical Officer	A — Grant or award	38.8K	$0.00	—	SEC
2026-05-18	Levy Adam D.	Chief Financial Officer	A — Grant or award	46.2K	$0.00	—	SEC
2026-05-18	TOMSICEK MICHAEL JOHN	Insider	A — Grant or award	9.4K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Acrivon Therapeutics, Inc. (ACRV). Updated in real time as new filings are submitted to the SEC.

Most-Active ACRV Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Blume-Jensen Peter	5	$28K
Miller Mary	3	$1K
RA CAPITAL MANAGEMENT, L.P.	3	$7.00M
Magovcevic-Liebisch Ivana	2	—
Devroe Eric	2	$1K

Recent ACRV Form 8-K Material Events

2026-06-17 — Item 5.02, 5.07, 9.01 [SEC]
2026-05-13 — Item 2.02, 9.01 [SEC]
2026-03-19 — Item 2.02, 7.01, 9.01 · Clinical · positive [SEC]
Acrivon Therapeutics announced financial results for Q4 and full year 2025, and provided a clinical update on its ACR-368 program. The company has initiated arm 4 of the Phase 2b registrational study in serous type endometrial cancer based on promising clinical data and biomarker
2026-03-02 — Item 1.02 · Contract · positive [SEC]
Acrivon Therapeutics terminated its OncoSignature Companion Diagnostic Agreement with Akoya Biosciences (Quanterix subsidiary) effective February 25, 2026, following completion of its own CLIA-certified laboratory. The termination involves no financial payments and includes a tra
2026-02-27 — Item 7.01, 9.01 · Clinical · neutral [SEC]
Acrivon held a live webcast KOL panel discussion at the European Society of Gynecological Oncology (ESGO) Congress on February 27, 2026, presenting interim data from the ACR-368 Phase 2b registrational-intent trial in endometrial cancer. The presentation included clinical data ov

Recent Insider Filings

2026-06-22 — RA CAPITAL MANAGEMENT, L.P. (Insider)
2026-06-22 — TOMSICEK MICHAEL JOHN (Insider)
2026-06-22 — Shacham Sharon (Insider)
2026-06-22 — Palani Santhosh (Insider)
2026-06-22 — Magovcevic-Liebisch Ivana (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ACRV insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ACRV Insider Trading — FAQ

What is the latest insider trade for ACRV?: Acrivon Therapeutics, Inc. (ACRV) had 29 insider filings in the last 90 days, with the most recent on 2026-06-22. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ACRV stock?: 0 insider purchases of ACRV were filed in the last 90 days.
How many insiders are selling ACRV stock?: 0 insider sales of ACRV were filed in the last 90 days.
Where can I see ACRV SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ACRV SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live ACRV dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.